GlassScriptPhysician profile
John H Hajjar
NPI 1104894435
$8,598.47
in general payments reported to CMS, 2019-2025
21 companies · $825 in 2025
The $825 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $1,973 · 2021: $14.43 · 2022: $295 · 2023: $4,166 · 2024: $1,208 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $4,470 · Food and Beverage: $1,561 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $4,470.37 |
| Food and Beverage | $1,561.02 |
| Education | $167.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $4,510.80 | 2022-2024 | Evis Exera Lll Colonovideoscope, Evis Exera III Video System Center, Olympus |
| Allergan, INC. | $1,960.00 | 2020 | |
| Astellas Pharma US INC | $328.56 | 2022-2023 | Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $318.30 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $312.80 | 2023-2025 | Gemtesa |
| Janssen Biotech, INC. | $285.54 | 2024-2025 | Erleada, Rybrevant, Carvykti |
| Antares Pharma, INC. | $176.58 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Astrazeneca Pharmaceuticals LP | $117.19 | 2019 | |
| Axonics, INC. | $92.66 | 2023-2024 | Axonics |
| Ferring Pharmaceuticals INC. | $73.18 | 2025 | Adstiladrin |
| Otsuka America Pharmaceutical, INC. | $66.25 | 2024-2025 | Jynarque |
| Teleflex LLC | $57.27 | 2021-2025 | Barrigel |
| Tolmar, INC. | $55.22 | 2024-2025 | Eligard, Jatenzo |
| Endo USA, INC. | $53.95 | 2025 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $47.07 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $45.72 | 2023 | |
| Halozyme INC | $31.97 | 2023 | |
| Acerus Pharmaceuticals Corporation | $25.77 | 2022 | |
| Endo Pharmaceuticals INC. | $13.89 | 2023 | Xiaflex, Aveed |
| Neotract INC. | $13.01 | 2020 | |
| Abbvie INC. | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hajjar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.